Researchers tested the novel antibody-drug conjugate trastuzumab duocarmazine in patients with heavily pretreated HER2-expressing metastatic cancers, including breast cancer.
HER2-Positive Breast Cancer
After more than 7 years of follow-up, the phase III PHARE trial failed to show that 6 months of adjuvant trastuzumab therapy was noninferior to 12 months in patients with HER2+ early breast cancer.
A phase II trial tested docetaxel, trastuzumab, and pertuzumab vs T-DM1 for the neoadjuvant treatment of HER2+ breast cancer.
This phase III trial tested T-DM1 plus pertuzumab vs chemotherapy and dual HER2 blockade in patients with HER2+ breast cancer.
Researchers tested a novel antibody-drug conjugate known as trastuzumab deruxtecan in an expansion cohort of a phase I study of patients with advanced HER2+ breast cancer previously treated with trastuzumab emtansine.
Researchers tested whether certain patients with HER2-positive breast cancer may eventually be eligible for non-surgical management.
The long-term results of the phase III HannaH trial confirmed the similarity between the subcutaneous and intravenous formulation of trastuzumab in patients with HER2+ breast cancer.
Researchers tested omitting chemotherapy from a treatment regimen involving dual blockade with pertuzumab and trastuzumab in patients with metastatic HER2+ breast cancer.
The combination of trastuzumab and paclitaxel 'represents an important step forward in de-escalating therapy' for HER2+ breast cancer.
A genomic and proteomic analysis of HER2+ breast cancer cell lines that are resistant to trastuzumab found a deregulation of the cell death pathway known as TRAIL.